All In Biotech

Drug Trial Radar · NCT02648672

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects

Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Dec 2015

Primary completion

Feb 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Tetra Discovery PartnersIndustry
Sponsor type
Industry
First posted
Jan 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female subjects. Each subject will be randomized to receive either a single dose of BPN14770 or placebo.

Conditions

  • Alzheimer's Disease

Interventions

  • BPN14770Drug

    BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jasper Clinic

    Kalamazoo, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.